The combination of EGCG and anti-HER2 therapies, namely pertuzumab or temsirolimus, abrogates anti-HER2 drug resistance in breast cancer models in vitro and in vivo, showing the role of EGCG not only in chemoprevention, but also as a therapeutic agent and suggesting the involvement of the epigenome reprogramming in acquired resistance (95). The gene discussed is ERBB2; the disease is breast carcinoma.